



CURRICULUM VITAE

Dr SANDRA KRSTAJIĆ, MRCP

- Diploma of Membership of Royal College of Physicians of UK
- Specialist in Internal Medicine
- Subspeciality Oncology
- Director and Owner of the private clinic Oncomed-System

PERSONAL DATA:

DOB: 08/06/1972.
DRIVING LICENCE
DUAL NATIONALITY: SERBIAN/BRITISH
FLUENT IN ENGLISH

CONTACT: tel No: + 38 1 64 408 8376,

e-mail: sandra.krstajic@gmail.com

EDUCATION:

Grammar School, A levels (equivalent): Biology A, Chemistry ,PhysicsA
Medical School, University of Belgrade, Serbia, graduated 1998, with
Honours (average mark 9.28/out of 10)
Medical rotation in Internal Medicine, University of Manchester, UK
Medical School, University of Belgrade, subspeciality training in
ONCOLOGY, 2012-2014

MEMBERSHIP

Full registration with UK General Medical Council
Full licence with Serbian Medical Chamber/Specialist in Internal Medicine
Member of Association of Medical Oncologists of Serbia (UMOS)
Member of British Medical Association
ESMO Member

EMPLOYMENT RECORD- fully practising medicine since graduation 1998.

-ONCOMED-SYSTEM, specialized private hospital for internal medicine, Director and owner Jan 2012- .

-IRVA CLINIC, Belgrade, Serbia, April 2008- Nov 2012.

specialized private hospital for internal medicine, Department of Medical Oncology and Palliative Care;

-US Embassy Belgrade, part-time medical consultant since 2006.

-BEL MEDIC, Belgrade, general hospital, Nov 2005- April 2008;

-MANCHESTER ROYAL INFIRMARY and Christie Hospitals, Manchester, England, Feb 2002-Aug 2005:

Medical rotation in internal medicine, rotating between departments of:

- cardiology
- respiratory medicine
- haematology/medical oncology
- acute internal medicine

-ROYAL OLDHAM HOSPITAL, Trafford General Hospital, Manchester, England, April 2001-Feb 2002, Emergency Medicine Unit;

-MEDEVAL-Contract Research Organisation /ASTRA ZENECA, Manchester, ENGLAND, work on clinical trials, Phase I and II, 2000.

- NATIONAL CANCER RESEARCH CENTER (Institut za onkologiju i radiologiju Srbije), Belgrade, Serbia, December- 1998-May 1999., goverment grant for research and education in medical oncology.

PROFESSIONAL PROFILE:

-medical oncology: diagnostics and medical treatment,chemotherapy implementation of modern ways of application of chemotherapy via port-a-cath systems,

- palliative care;

- general internal medicine,

-ultrasonography: diagnostics and most ultrasounded guided interventions;

-acute and emergency medicine.

EXAMS /COURSES:

1. **10th ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY**, Ermatingen, Switzerland, April, 2011.
2. **ESO Lung Cancer, Visiting professor, Belgrade, March 2013.**
3. **ESO school Women s Cancer ,Ribarska Banja, April 2013.**

4. **DIPLOMA IN PALLIATIVE CARE**, Bel Hospice, Belgrade, Nov 2009-Dec 2009,mentor Dr. Nataša Milićević, consultant in medical oncology and palliative care;
5. **DIPLOMA in ABDOMINAL AND SOFT TISSUES ULTRASONOGRAPHY**, October 2006-July 2007, mentor Prof. M. Perišić, University Clinical Center of Serbia;
6. **DIPLOMA of MEMBERSHIP of ROYAL COLLEGE of PHYSICIANS of UK, April 2004;**
7. **CERTIFICATION in ADVANCED LIFE SUPPORT COURSES /ALS;**
8. **PLAB TEST: Jan 2001., set by GMC of UK;**
9. **IELTS (International English Language Testing System, academic module), 2000.**

RESEARCH and PAPER

Project Manager in clinical trials Medeval/Astra Zeneca , Manchester, August 1999-Jan 2000.

Involved in clinical trial 5-FU/CAMPTO , National Cancer Research Center 1999.
AUDIT: Assessment of ALS in pre-hospital and A/E environment; Treatment of Paracetamol OD.

Abstract:Toxicity cutaneous reaction to Docetaxel after a previous hypersensitivity reaction to Paclitaxel
accepted by ESO Masterclass in Clinical Oncology, Montenegro, 2009.

Abstract: Triple-negative breast cancer: targeted therapy, ESO Masterclass in Clinical Oncology, Switzerland, April 2011.

Totally implantable central venous catheters of the port-a-cath type:
complications due to its use in the treatment of cancer patients, JBUON, Sept 2014.

Clinical trials:

P.I. A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin (AVANA)

S.C. Galaxi, A Randomised, Parallel, Double Blinded Study, Sponsor: Janssen Research and Development, LLC, Protocol: CNTO1959CRD3001

REFERENCES:

Prof dr. V. Kovčín, consultant medical oncologist; Clinical Medical Center Bežanijska Kosa, Belgrade

Prof dr M.Granić, consultant surgical oncologist, Clinical Medical Center Bežanijska Kosa, Belgrade

Dr Lj. Stamatović, consultant medical oncologist, National Cancer Research Center, Belgrade

Dr D. Radosavljevic, consultant medical oncologist, National Cancer Research Center, Belgrade

Prof.dr Dirk Arnold, consultant medical oncologist, Germany

Dr J. Simpson, consultant in respiratory medicine, Manchester Royal Infirmary, Manchester, England

US Embassy Belgrade, Health Unit, contact:Ms.Natasa Jankovic